Table 1.
Comparative description of the clinical parameters of the Institut Curie, AOCS and TCGA cohorts of HGSOC patients
| CURIE | AOCS | TCGA | CURIE | |
|---|---|---|---|---|
| Type of analysis | Transcriptomic | Transcriptomic | Transcriptomic | IHC |
| Number of patients | 107 | 285 | 484 | 118 |
| Date of inclusion | 1989−2005 | 1992−2006 | 1994−2011 | |
| Age at diagnostic | ||||
| Median age (years) | 58 | 59 | 59 | 60 |
| Range (years) | 31−87 | 22−80 | 30−87 | 35−80 |
| Histotype | ||||
| Serous | 82 (76.5%) | 264 (92.6%) | 484 (100%) | 115 (97.4%) |
| Endometrioïd | 8 (7.5%) | 20 (7%) | 2 (1.7%) | |
| Mucinous | 8 (7.5%) | 1 (0.8%) | ||
| Clear cell | 6 (5.5%) | |||
| Carcinosarcoma | 2 (2%) | |||
| Brenner tumor | 1 (1%) | |||
| Adenocarcinoma | 1 (0.4%) | |||
| Figo substage | ||||
| I | 21 (19.6%) | 24 (8.4%) | 7 (5.9%) | |
| II | 10 (9.35%) | 18 (6.3%) | 24 (5%) | 9 (7.6%) |
| III | 59 (55.14%) | 217 (76.1%) | 377 (77.9%) | 82 (69.5%) |
| IV | 17 (15.9%) | 22 (7.7%) | 78 (16.1%) | 13 (11.01%) |
| NA | 4 (1.4%) | 5 (1%) | 7 (5.9%) | |
| Grade | ||||
| 1 | 7 (6.5%) | 19 (6.7%) | ||
| 2 | 34 (31.5%) | 97 (34%) | 57 (11.8%) | 31 (26.3%) |
| 3 | 66 (62%) | 164 (57.5%) | 415 (85.7%) | 87 (73.7%) |
| NA | 5 (1.8%) | 12 (2.5%) | ||
| Surgery | ||||
| Full | 38 (36%) | 84 (29.5%) | 88 (18.2%) | 32 (27.1%) |
| Partial | 69 (64%) | 164 (57.5%) | 339 (70%) | 82 (69.5%) |
| NA | 37 (13%) | 57 (11.8%) | 4 (3.4%) | |
| Clinical response | ||||
| RC—Complete response | 51 (47.7%) | 273 (56.4%) | 47 (39.8%) | |
| RP—Partial response | 22 (20.6%) | 57 (11.8%) | 31 (26.3%) | |
| S—Stability | 7 (6.5%) | 25 (5.2%) | 7 (5.9%) | |
| P—Progression | 11 (10.3%) | 36 (7.4%) | 3 (2.6%) | |
| NA | 16 (15%) | 93 (19.2%) | 30 (25.4%) |
The first three columns recapitulate clinical parameters from cohorts used for transcriptomic data analyses. TCGA, AOCS and Curie cohorts have previously been described6–8. The last column concerns samples used for immunohistochemistry analyses. Tumor samples were obtained from a cohort of consecutive ovarian carcinoma patients, treated at the Institut Curie between 1989 and 2012. All analyzed samples have been collected prior to any chemotherapeutic treatment. Indeed, for each patient, a surgical specimen was taken, before chemotherapy, for pathological analysis and tumor tissue cryopreservation. The median patient’s age was 60 years (with a range of 35–80 years). Ovarian carcinomas were classified according to the World Health Organization histological classification of gynecological tumors. Pathological analysis identified 115 high-grade serous tumors (97.4%), 2 high-grade endometrioïd tumors (1.7%) and 1 high-grade mucinous tumor (0.8%). Sixteen subjects (13.5%) were considered as early stage (International Federation of Gynecology and Obstetrics (FIGO) I−II) and 95 subjects (80.5%) were considered as advanced stage (III and IV) of disease. Patients were treated with a combination of surgery and chemotherapy, the latter including alkylating or alkylating-like agents ± taxane as a first-line treatment in most cases. All the subjects underwent surgery, 82 of them have a partial debulking and 32 subjects have a full debulking